生物防衛市場の規模、シェア、動向、成長、予測（2026年～2034年）

Fortune Business Insightsによると、世界のバイオディフェンス市場規模は2025年に162億3000万米ドルと評価されました。同市場は2026年の177億5000万米ドルから2034年には268億8000万米ドルに成長すると予測されており、予測期間中の年平均成長率（CAGR）は5.32%です。北米は2025年に42.97%の市場シェアを占め、世界のバイオディフェンス市場を牽引しました。バイオテロ、新興感染症、生物兵器、世界的なパンデミックへの備えに対する懸念の高まりが、高度な生物防御技術、ワクチン、治療薬、病原体検出システムへの投資を促進しています。

生物防衛市場の概要

生物防衛市場は、生物学的脅威の予防、検知、監視、および対応を目的とした技術、製品、およびソリューションで構成されています。これらの脅威は、感染症の発生による自然発生、生物学的事故による偶発的な発生、またはバイオテロや生物兵器による意図的な発生によって生じる可能性があります。生物防衛への取り組みは、国家安全保障の強化、公衆衛生の保護、実験室の安全性の向上、および効果的な医療対策の開発に重点を置いています。

各国政府や医療機関が、新興感染症や潜在的な生物学的脅威への備えをますます重視するようになるにつれ、この市場の重要性が高まっている。ワクチン開発、迅速診断技術、バイオサーベイランスネットワーク、除染装置、防護システムへの投資が、業界の拡大に貢献している。

さらに、製薬会社やバイオテクノロジー企業は、革新的なワクチン、治療法、診断ソリューションを開発するために、研究開発能力を強化している。政府機関、研究機関、防衛組織、民間企業間の連携も、高度な生物兵器対策能力の開発を支えている。

主要な市場推進要因

バイオテロと生物学的脅威に対する懸念の高まり

生物兵器、バイオテロ、感染症の発生に対する懸念の高まりは、市場成長を支える主要因の一つである。世界各国の政府は、軍人、一般市民、医療インフラ、そして重要な資源を守るため、生物兵器対策能力を強化している。

感染症の発生とCOVID-19パンデミックの経験は、効果的な疾病監視、迅速な診断、および緊急事態への備えの重要性を浮き彫りにしました。そのため、政府機関はワクチン備蓄、生物学的脅威の検出、および公衆衛生対応プログラムに、より多くの資源を投入しています。

生物兵器対策プログラムへの政府投資の増加

政府による資金援助と国家安全保障上の取り組みは、世界の生物兵器対策産業の拡大において重要な役割を果たしている。各国政府は、研究開発、高度な検出システム、医療対策、緊急対応インフラに投資を行っている。

例えば、2025年4月、パーソンズ社は海軍医療研究司令部から、感染症の迅速な検出に関する研究を改善するための2400万米ドルの契約を獲得した。こうした取り組みは、生物学的脅威への備えと国家安全保障の強化に対する重視が高まっていることを示している。

さらに、米国では、プロジェクト・バイオシールドや生物医学先端研究開発局（BARDA）などのプログラムが、医療対策の開発、調達、備蓄を支援している。

バイオテクノロジーと診断技術の進歩

バイオテクノロジー、人工知能、機械学習、バイオセンサー技術における技術革新は、新たな成長機会を生み出している。最新の診断技術は、生物学的脅威をより迅速に特定することを可能にし、医療機関や防衛機関が潜在的な感染症の発生に対応する能力を向上させている。

Companies are increasingly focusing on developing advanced biosensors, rapid diagnostic platforms, pathogen identification technologies, and automated surveillance systems. These innovations are expected to strengthen biological threat monitoring and response capabilities.

Request a Free Sample: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biodefense-market-113684

Biodefense Market Trends

Growing Adoption of Artificial Intelligence and Machine Learning

Artificial intelligence and machine learning are emerging as important technologies in the biodefense market. These technologies support pathogen identification, outbreak prediction, biological risk assessment, and real-time surveillance.

AI-assisted surveillance systems can help organizations analyze large volumes of biological and epidemiological information, identify unusual patterns, and improve emergency response planning. The integration of AI into biosurveillance networks is expected to enhance the accuracy and efficiency of biological threat detection.

Increasing Demand for Advanced Biosensors

Biosensors are gaining importance because of their ability to detect biological threats rapidly and accurately. These technologies can identify pathogens and toxins in different environments, supporting applications in healthcare facilities, military operations, border security, and research laboratories.

Continuous improvements in sensor miniaturization, portability, sensitivity, and detection capabilities are supporting the adoption of advanced biosensors. Their ability to provide timely information is particularly important for responding to infectious disease outbreaks and potential biological incidents.

Growing Focus on Vaccine Development and Medical Countermeasures

The increasing threat of emerging infectious diseases is encouraging pharmaceutical and biotechnology companies to invest in vaccines, therapeutics, and diagnostic solutions.

Governments are also prioritizing the availability of medical countermeasures to improve preparedness against biological emergencies. Advanced vaccine platforms and rapid drug development technologies are expected to play an important role in strengthening global biodefense capabilities.

Biodefense Market Segmentation Analysis

The market is segmented by technology, system, and end user.

By Technology

Based on technology, the market is categorized into UV light, gamma radiation, cold plasma, microwave heating, and others.

The UV light segment accounted for the largest market share in 2025 and is also estimated to be the fastest-growing segment during the forecast period. UV light technology is widely used for disinfection and sterilization because of its ability to inactivate microorganisms, including bacteria, viruses, and fungi.

Increasing awareness regarding infection prevention, healthcare facility sanitation, and biological security is supporting demand for UV-based solutions. Growing investments in advanced sterilization technologies are expected to strengthen segmental growth.

By System

Based on system, the market is divided into digital biosurveillance networks, early warning systems, biohazard detection systems, AI-assisted surveillance systems, biosensors, and others.

The biohazard detection systems segment is projected to account for 35.19% of the market share in 2026. Increasing concerns regarding bioterrorism, infectious disease outbreaks, and biological threats are encouraging organizations to adopt advanced detection technologies.

Meanwhile, the biosensors segment is estimated to register the fastest growth during the forecast period. Improvements in sensor technology, portability, and pathogen identification capabilities are supporting its adoption across healthcare, defense, and research applications.

By End User

Based on end user, the market is categorized into military forces, homeland security, hospitals and clinics, pharmaceutical and biotechnology companies, and virological research institutes.

The military forces segment is projected to dominate the market with a 36.61% share in 2026. Increasing military preparedness against biological warfare, infectious diseases, and potential bioterrorism incidents is driving demand for protective equipment, vaccines, detection technologies, and medical countermeasures.

The pharmaceutical and biotechnology companies segment is expected to experience the fastest growth during the forecast period. Increasing investments in vaccine development, therapeutics, and diagnostic technologies are creating opportunities for pharmaceutical and biotechnology companies.

Biodefense Market Regional Outlook

North America

North America dominated the global biodefense market in 2025, reaching USD 6.97 billion and accounting for 42.97% of the global market share. The regional market is projected to increase to USD 7.65 billion in 2026.

The region's leadership is supported by substantial government investments, established biotechnology infrastructure, advanced research capabilities, and strong collaboration between public and private organizations.

The U.S. plays a significant role in regional market development through investments from agencies such as the Department of Defense, Department of Homeland Security, and BARDA. Government initiatives focused on vaccine development, biological threat monitoring, and emergency preparedness are further supporting market expansion.

Europe

Europe accounted for USD 3.80 billion in 2025, representing 23.43% of the global biodefense market. The regional market is expected to reach USD 4.20 billion in 2026.

Europe is projected to be the fastest-growing regional market during the forecast period. Increasing government funding for biosecurity, growing awareness of biological threats, and advancements in biotechnology are supporting regional expansion.

Initiatives involving the European Health Emergency Response Authority (HERA) and investments in biological threat preparedness are strengthening the region's capabilities. Furthermore, growing investments in research and development and advanced surveillance technologies are creating additional growth opportunities.

Asia Pacific

The Asia Pacific biodefense market was valued at USD 4.05 billion in 2025 and accounted for 24.95% of the global market. The regional market is projected to reach USD 4.41 billion in 2026.

Growing public health concerns, expanding healthcare infrastructure, geopolitical uncertainties, and increasing government investments in biological security are supporting regional market growth.

Countries such as China, India, and Japan are strengthening their disease surveillance capabilities and investing in medical countermeasures. Increasing attention toward pandemic preparedness and biotechnology research is expected to create significant opportunities across the region.

Middle East & Africa

The Middle East & Africa market accounted for USD 1.06 billion in 2025, representing 6.55% of the global market. The regional market is projected to reach USD 1.14 billion in 2026.

Growing awareness of infectious diseases, government initiatives, and increasing investments in biotechnology are contributing to market development. Governments are focusing on improving healthcare preparedness, strengthening laboratory infrastructure, and developing capabilities to respond to biological emergencies.

Latin America

The Latin America biodefense market reached approximately USD 0.34 billion in 2025, accounting for 2.09% of the global market. The market is expected to reach USD 0.36 billion in 2026.

Increasing government investments in public health safety, decentralized testing, and infectious disease monitoring are supporting regional growth. The growing need for diagnostic solutions to address diseases such as dengue, chikungunya, and Zika is also encouraging investments in advanced healthcare technologies.

Competitive Landscape of the Biodefense Market

The global biodefense market is characterized by competition among pharmaceutical companies, biotechnology manufacturers, diagnostic technology providers, and specialized defense solution developers. Major companies are focusing on product innovation, strategic collaborations, research investments, and acquisitions to strengthen their market positions.

Market participants are increasingly investing in vaccine development, medical countermeasures, biological detection systems, decontamination technologies, and biosurveillance platforms.

Key companies operating in the global biodefense market include:

1. AirBoss Defense Group, Inc. (U.S.)

2. Bioquell, An Ecolab Solution (U.S.)

3. Bio-Rad Laboratories, Inc. (U.S.)

4. BlueDot Inc. (Canada)

5. E4life Srl (Australia)

6. Emergent BioSolutions Inc. (U.S.)

7. SIGA Technologies, Inc. (U.S.)

8. Dynavax Technologies (U.S.)

9. Alnylam Pharmaceuticals, Inc. (U.S.)

10. Bavarian Nordic A/S (Denmark)

11. SKAN AG (Switzerland)

12. Smiths Detection Group Ltd. (U.K.)

13. Parsons Corporation (U.S.)

Read Report Insights: https://www.fortunebusinessinsights.com/biodefense-market-113684

'Future Outlook of the Biodefense Market

The future of the global biodefense market is expected to be shaped by increasing biological security concerns, technological advancements, and government investments in public health preparedness. The growing possibility of infectious disease outbreaks and biological threats is encouraging countries to strengthen their detection, prevention, and response capabilities.

The integration of artificial intelligence, machine learning, biosensors, and advanced diagnostic platforms is expected to improve biological surveillance and threat identification. Furthermore, growing investments in vaccine development, therapeutics, and medical countermeasures will create new opportunities for pharmaceutical and biotechnology companies.

However, high research and development costs, lengthy regulatory approval procedures, and uncertainties regarding product commercialization may challenge market expansion. Despite these limitations, increasing global emphasis on biological security and pandemic preparedness is expected to support the market's growth through 2034.

Frequently Asked Questions (FAQs)

1. What is the global biodefense market size?

According to Fortune Business Insights, the global biodefense market was valued at USD 16.23 billion in 2025. It is projected to grow from USD 17.75 billion in 2026 to USD 26.88 billion by 2034.

2. What is the expected CAGR of the biodefense market?

The global biodefense market is expected to register a CAGR of 5.32% during the forecast period of 2026–2034, driven by increasing biological security concerns, government investments, and technological advancements.

3. Which segment dominates the biodefense market?

The military forces segment dominates the market by end user and is projected to account for 36.61% of the global market share in 2026. Increasing military preparedness and demand for biological threat countermeasures are supporting its leadership.

4. Which region dominates the global biodefense market?

North America dominates the global biodefense market. The region accounted for 42.97% of the market in 2025, supported by substantial government funding, advanced biotechnology infrastructure, and strong research and development capabilities.

5. What are the major trends shaping the biodefense market?

主な傾向としては、人工知能と機械学習の普及拡大、高度なバイオセンサーへの需要増加、デジタルバイオサーベイランスネットワークの拡大、ワクチン開発への投資増加、そして病原体の迅速な検出とパンデミックへの備えへの注目の高まりなどが挙げられる。

日本の市場機会を探る - 最新情報 - 生物防衛市場 - インサイト